Things we do for no reason™: Routine use of unfractionated heparin for initial anticoagulation in venous thromboembolism.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 42007523.
- Also identified by DOI 10.1002/jhm.70331.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Venous thromboembolism is common among hospitalized patients. Current guidelines recommend direct oral anticoagulants and low-molecular-weight heparin (LMWH) as first-line therapy for most patients based on superior efficacy and ease of use. Compared with unfractionated heparin (UFH), LMWH provides more predictable anticoagulation, achieves therapeutic levels rapidly with weight-based dosing, and requires minimal laboratory monitoring. Randomized trials and observational studies demonstrate that LMWH is associated with lower rates of recurrent venous thromboembolism (VTE), bleeding, and heparin-induced thrombocytopenia. For most patients requiring parenteral anticoagulation, routine use of UFH should be avoided in favor of LMWH.